NanoViricides raises ~$3.8M in registered direct offering of common stock and warrants

NANOVIRICIDES, INC.

Gross proceeds of ~$3.8M from sale of 2,516,339 shares (or pre-funded warrants) and warrants to purchase 2,516,339 shares at $1.75.
Offering closed on July 27, 2026; net proceeds for working capital, R&D, clinical trials, and strategic purposes.
CEO and principal stockholder TheraCour Pharma entered 30-day lock-up agreements restricting share sales.
D. Boral Capital acted as exclusive placement agent with 7.0% cash fee and up to $50,000 expense reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.